NCT04627142View on ClinicalTrials.gov

A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
DRUG

BI 1701963

Tablet

DRUG

Camptosar®

Solution for infusion

Trial Locations (1)

200120

Shanghai East Hospital, Tongji University China, Shanghai

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04627142 - A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation | Biotech Hunter | Biotech Hunter